FDA approves Sanofi and Merck's 6-in-1 pediatric vaccine

Jan 02, 2019

The U.S. Food and Drug Administration has approved Vaxelis, a six-in-one vaccine  for use in children from six weeks through four years of age. Vaxelis was developed as part of a joint-partnership between Sanofi and Merck.

The drugmakers will not make commercial supply available prior to 2020 and are working to maximize production of Vaxelis to allow for a sustainable supply to meet anticipated U.S. demand.

Vaxelis is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b. Vaxelis is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday). The vaccine is contraindicated in children with a history of severe allergic reaction to a previous dose of Vaxelis, any ingredient of Vaxelis, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine or H. influenzae type b vaccine.

Read the full release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments